Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183664 | 0.77 | LOXL2 (0.41) | LOXL2HSD17B10ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7861187 | 0.77 | LOXL2 (0.41) | LOXL2HSD17B10ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13986255 | 0.77 | LOXL2 (0.37) | LOXL2HSD17B10ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL58206 | 0.76 | TSHR (0.52) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL444619 | 0.74 | LOXL2 (0.38) | LOXL2HSD17B10ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL791964 | 0.73 | — | — | |
| SCHEMBL353572 | 0.73 | IDO1 (0.52) | LOXL2ALDH1A1 | |
| SCHEMBL3352453 | 0.73 | IDO1 (0.52) | HRH1 | |
| SCHEMBL8743208 | 0.73 | IDO1 (0.52) | ALDH1A1 | |
| SCHEMBL6875901 | 0.72 | ADRB2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787576-B2 | Method for the preparation of a coating comprising oligomeric alkynes | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3599239-A1 | METAL ORGANIC FRAMEWORKS AND METHODS FOR USING THEREOF | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO (CH) | 2020-01-29 | — | — | EP | disclosed |
| US-20190048202-A1 | METHOD FOR THE PREPARATION OF A COATING COMPRISING OLIGOMERIC ALKYNES | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20180171152-A1 | METHOD FOR THE PREPARATION OF A COATING | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2018-06-21 | — | — | US | disclosed |
| EP-3303482-A1 | METHOD FOR THE PREPARATION OF A COATING | Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016189047-A1 | METHOD FOR THE PREPARATION OF A COATING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016174266-A2 | METHOD FOR THE PREPARATION OF A COATING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2016-11-03 | — | — | WO | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0960096-A1 | SUBSTITUTED $g(b)-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999038844-A1 | METHOD FOR PREPARING AN N-[(ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE COMPOUND AND A CYCLYZED COMPOUND | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998032734-A1 | SUBSTITUTED β-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | LOXL2 3777/4885HSD17B10 2139/4885ALDH1A1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.